Swiss Rockets AG

Swiss Rockets AG is a Basel-based biotechnology incubator and accelerator founded in 2018. The company focuses on identifying, investing in, and nurturing promising biotech startups in Switzerland, Europe, and the United States. Their mission is to develop groundbreaking medicines that transform the treatment of cancer, infectious diseases, and autoimmune disorders, striving for more effective, equitable, and accessible healthcare worldwide.

The firm offers a comprehensive suite of services to its portfolio companies, including financial resources, mentorship, drug development expertise, and guidance on business and management topics. They provide access to state-of-the-art facilities and technologies to accelerate product development, as well as a vast network to connect portfolio companies with strategic partners and investors. Their unique approach involves a rigorous screening process to identify startups with the most promising technologies and strong teams.

Swiss Rockets AG has demonstrated a commitment to innovation through strategic partnerships, such as the one announced in October 2025 with Squirro AG, a leading Swiss enterprise AI company. This collaboration aims to drive the AI transformation of Swiss Rockets by introducing Squirro's Generative AI Platform as the backbone of their digital knowledge ecosystem, supporting the group's mission to accelerate innovation, streamline research processes, and enhance decision-making across its biotech portfolio.